Equities

Nang Kuang Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1752:TAI

Nang Kuang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)36.45
  • Today's Change-0.05 / -0.14%
  • Shares traded82.68k
  • 1 Year change-13.42%
  • Beta0.0220
Data delayed at least 20 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

NANG KUANG PHARMACEUTICAL CO., LTD. is principally engaged in the manufacture, processing and trading of western medicine. The company main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The Company is also engaged in the manufacture, processing and trading of medical equipment. The Company distributes its products within the domestic market and to overseas markets.

  • Revenue in TWD (TTM)2.22bn
  • Net income in TWD257.07m
  • Incorporated1973
  • Employees552.00
  • Location
    Nang Kuang Pharmaceutical Co LtdNo.1001, Zhongshan Road, Xinhua DistrictTAINAN 712TaiwanTWN
  • Phone+886 65984121
  • Fax+886 65981845
  • Websitehttps://www.nangkuang.com.tw/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vetnostrum Animal Health Co Ltd1.37bn119.57m2.63bn185.0020.782.0113.551.921.741.7419.7717.950.91652.786.487,399,816.008.007.649.8110.1031.8531.008.739.192.1873.650.017449.577.173.6849.153.98-30.60--
Phytohealth Corp138.46m-59.76m2.76bn84.00--1.50--19.94-0.3009-0.30090.69719.300.05770.65173.26---4.15-4.59-5.23-5.7938.6443.87-71.96-71.8226.02--0.008---5.499.97-56.00---6.44--
BRIM Biotechnology Inc2.92m-387.70m3.55bn----1.97--1,215.39-3.03-3.030.022713.540.0017--0.2562---22.31-30.03-23.29-32.3645.70---13,405.20-1,623.0627.36-1,899.890.0111---75.56--54.15--310.04--
Nang Kuang Pharmaceutical Co Ltd2.22bn257.07m3.69bn552.0014.371.528.351.662.542.5421.9824.030.60732.198.36--7.026.6410.089.5636.3434.5011.5611.940.708410.040.223180.052.314.5422.682.2852.41-1.21
Formosa Pharmaceuticals Inc12.16m-74.25m4.27bn----2.82--350.63-0.5083-0.50830.081810.000.0057--4.64---3.49-30.53-3.80-33.884.52---610.20-758.219.55--0.0161--359.89163.5237.56--103.21--
Data as of Feb 06 2026. Currency figures normalised to Nang Kuang Pharmaceutical Co Ltd's reporting currency: Taiwan Dollar TWD

Institutional shareholders

1.29%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 08 Jan 20261.19m1.18%
American Century Investment Management, Inc.as of 08 Jan 202679.00k0.08%
Dimensional Fund Advisors Ltd.as of 30 Nov 202527.80k0.03%
DFA Australia Ltd.as of 30 Nov 20252.87k0.00%
More ▼
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.